Document Detail

Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.
MedLine Citation:
PMID:  12172746     Owner:  NLM     Status:  MEDLINE    
Described here is the case of a patient with infective endocarditis in a prosthetic valve due to a Mycobacterium fortuitum-group organism. The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacterium fortuitum-group endocarditis, and the first of survival without surgical intervention. The duration of treatment is not well defined for this patient, but life-long suppressive therapy will likely be required.
M Kunin; F Salamon; M Weinberger; I Genkin; A Sagie; R Tur-Kaspa
Related Documents :
19674916 - Postoperative lipid-lowering therapy and bioprosthesis structural valve deterioration: ...
18981596 - Active infective endocarditis: management and risk analysis of hospital death from 24 y...
19324566 - Transapical aortic valve implantation in patients requiring redo surgery.
7646166 - Structural deterioration in carpentier-edwards standard and supraannular porcine biopro...
15371846 - Midline dorsal plication technique for penile curvature repair.
19117656 - Treatment of idiopathic retroperitoneal fibrosis with colchicine and steroids: a case s...
Publication Detail:
Type:  Journal Article; Review     Date:  2002-07-10
Journal Detail:
Title:  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology     Volume:  21     ISSN:  0934-9723     ISO Abbreviation:  Eur. J. Clin. Microbiol. Infect. Dis.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-08-12     Completed Date:  2003-01-03     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8804297     Medline TA:  Eur J Clin Microbiol Infect Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  539-41     Citation Subset:  IM    
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amikacin / therapeutic use
Anti-Bacterial Agents / therapeutic use
Ciprofloxacin / therapeutic use
Endocarditis, Bacterial / drug therapy*,  microbiology*
Heart Valve Prosthesis / microbiology*
Mycobacterium Infections / drug therapy*,  microbiology
Mycobacterium fortuitum / isolation & purification*
Prosthesis-Related Infections / drug therapy*,  microbiology*
Thienamycins / therapeutic use
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Thienamycins; 37517-28-5/Amikacin; 85721-33-1/Ciprofloxacin; 96036-03-2/meropenem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Wound Infection due to Vibrio vulnificus in Spain.
Next Document:  Changing distribution of Candida species isolated from sterile and nonsterile sites in Israel.